Delving into the Latest Updates on REGN-17092 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Regeneron Pharmaceuticals, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy participants. This is the first time that REGN17092 will be given to people.
Other aims are to assess:
How much of the study drug is in the blood at different times
Whether the body makes its own antibodies against the study drug (which could make the drug less effective or lead to side effects)

Start Date28 Nov 2023

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with REGN-17092

Login to view more data

100 Translational Medicine associated with REGN-17092

Login to view more data

100 Patents (Medical) associated with REGN-17092

Login to view more data

1

Literatures (Medical) associated with REGN-17092

01 Aug 2024·Clinical Microbiology and Infection

An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2

Review

Author: Franchini, Massimo ; Focosi, Daniele ; Maggi, Fabrizio ; Casadevall, Arturo

BACKGROUNDAnti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.OBJECTIVESWe review here the current pipeline of anti-spike mAb's, discussing in detail the most promising candidates.SOURCESWe scanned PubMed, ClinicalTrials.gov and manufacturers' press releases for clinical studies on anti-spike monoclonal antibodies.CONTENTWe present state-of-art data clinical progress for AstraZeneca's AZD3152, Invivyd's VYD222, Regeneron's REGN-17092 and Aerium Therapeutics' AER-800.IMPLICATIONSThe anti-spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions.

100 Deals associated with REGN-17092

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 1	Belgium	Regeneron Pharmaceuticals, Inc.	28 Nov 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data